Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · RenovoRx, Inc. (RNXT)

RenovoRx to join JonesTrading KOL webinar on pancreatic cancer on August 13, 2026

Neutral Impact 1 of 5 other Written later

RenovoRx announced it will take part in a JonesTrading key opinion leader webinar on pancreatic cancer and its TAMP technology platform on August 13, 2026, at 1:30 p.m. ET, with CEO Shaun Bagai as a speaker. The filing contains no financial results, guidance, or new clinical data, so it is an informational event announcement for shareholders.

Key points

  • Webinar is scheduled for Thursday, August 13, 2026, at 1:30 p.m. ET, moderated by JonesTrading analyst Justin Walsh.
  • Speakers include CEO Shaun Bagai and two oncologists, Dae Won Kim, MD, of Moffitt Cancer Center and Ravi Shridhar, MD, PhD, of AdventHealth Cancer Institute.
  • The release cites RenovoCath sales of approximately $1.1 million in 2025 and a record $563,000 in the first quarter of 2026.
  • A replay will be available on the company's investor relations website.

The filing

CompanyRenovoRx, Inc. (RNXT)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:10 PM ET
Accession number0001493152-26-035995

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.